8-K: FitLife Brands Reports First Quarter 2025 Results: Revenue and Earnings Decline Slightly

FitLife Brands announces a slight decrease in revenue and earnings for the first quarter of 2025, with total revenue at $15.9 million and net income at $2.0 million.

Summary

• FitLife Brands reported its financial results for the first quarter ended March 31, 2025.
• Total revenue was $15.9 million, a 4% decrease compared to the first quarter of 2024.
• Online sales accounted for 67% of total revenue, amounting to $10.6 million, which is a 2% decrease year-over-year.
• Wholesale revenue decreased by 7% to $5.3 million.
• Gross margin decreased from 44.0% to 43.1%.
• Net income was $2.0 million, compared to $2.2 million in the same period last year.
• Basic earnings per share were $0.22, and diluted earnings per share were $0.20.
• Adjusted EBITDA decreased by 6% to $3.4 million.
• The company's net debt stands at $6.0 million, representing approximately 0.4x adjusted EBITDA.
• Legacy FitLife revenue increased 5%, driven by an 11% increase in online revenue and a 2% increase in wholesale revenue.
• MRC revenue decreased 11%, with the Dr. Tobias brand declining 11% and skincare brands declining 14% (9% on a constant currency basis).
• MusclePharm revenue decreased 6%, with wholesale revenue decreasing 41% and online revenue increasing 33%.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue and earnings are down, the company highlights strong cash flow, deleveraging, and potential M&A opportunities. The mixed performance across different brands also contributes to the neutral sentiment.

Positives

• Legacy FitLife experienced a 5% revenue increase, driven by strong online sales growth.
• Legacy FitLife saw an increase in gross margin from 42.1% to 44.6%.
• The company's strong cash flow generation has allowed for further deleveraging of the balance sheet.
• MusclePharm's online revenue increased by 33%.

Negatives

• Total revenue decreased by 4% compared to the first quarter of 2024.
• Net income decreased from $2.2 million to $2.0 million.
• Adjusted EBITDA decreased by 6% compared to the same period in 2024.
• MRC revenue decreased by 11% compared to the same period in 2024.
• MusclePharm's wholesale revenue decreased by 41%.

Risks

• The company acknowledges that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially.
• The company's ability to continue to grow revenue and achieve positive cash flow is subject to various factors beyond its control.
• The decrease in wholesale revenue for MusclePharm was primarily due to one wholesale customer that took advantage of the company's promotional investment during the fourth quarter of 2024 without increasing their sell-through of the product, which affected their reorder volumes during the first quarter of 2025.
• Challenging year-over-year comparisons began in February of 2025 for the Dr. Tobias brand.

Future Outlook

The company is encouraged by its strong cash flow generation and financial flexibility to complete a sizable acquisition should a compelling opportunity arise. The current market environment has resulted in elevated deal flow, and the company continues to review a number of M&A opportunities.

Management Comments

• Dayton Judd, the company's Chairman and CEO, stated that the first quarter of 2025 was strong for the Legacy FitLife business but somewhat challenged for MRC and MusclePharm.
• He noted that orders from a large MusclePharm customer are higher thus far during the second quarter of 2025 than for all of the first quarter of 2025.
• He also highlighted that the company is encouraged by its continued strong cash flow generation, which has allowed for further deleveraging of the balance sheet.

Industry Context

The nutritional supplements and wellness products industry is highly competitive, with companies constantly innovating and marketing new products to health-conscious consumers. FitLife Brands competes with both large, established players and smaller, niche brands. The company's focus on online sales and strategic acquisitions is a common strategy in this industry to drive growth and expand market share.

Comparison to Industry Standards

• Comparing FitLife Brands' performance to industry peers requires considering factors like size, product focus, and distribution channels.
• Larger companies like Herbalife Nutrition and Nu Skin Enterprises have significantly higher revenue but also different cost structures and market strategies.
• Smaller, more focused companies might have higher growth rates in specific product categories but lack the scale and diversification of FitLife Brands.
• FitLife's adjusted EBITDA margin of approximately 21% (based on $3.4 million adjusted EBITDA on $15.9 million revenue) is a key metric to compare against peers.
• Companies like GNC, which FitLife distributes through, can provide a benchmark for retail distribution performance, while online-focused competitors offer insights into e-commerce effectiveness.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and earnings, but reassured by the company's strong cash flow and potential for future acquisitions.
• Employees may be affected by the performance of individual brands, with potential implications for job security and compensation.
• Customers may see changes in product offerings and pricing as the company adjusts its strategies for different brands.
• Suppliers may experience fluctuations in order volumes based on the performance of the company's brands.
• Creditors may be reassured by the company's deleveraging efforts and strong cash flow.

Next Steps

• The company will hold an investor conference call on May 15, 2025, at 4:30 pm ET.
• Management intends to continue reviewing M&A opportunities.

Key Dates

Keywords

FitLife Brands, financial results, nutritional supplements, wellness products, revenue, EBITDA, net income, online sales, wholesale revenue, gross margin, Legacy FitLife, MRC, MusclePharm